First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Sponsor: IQVIA Biotech
Terminated
discontinued development program
Other terminated trials from IQVIA Biotech
Other Nonsmall Cell Lung Cancer trials with similar outcome
Listed as NCT04396340, this PHASE1 trial focuses on Nonsmall Cell Lung Cancer and Ovarian Cancer and remains terminated or withdrawn. Sponsored by IQVIA Biotech, it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Nov 2023 — Apr 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- IQVIA Biotech
- Mersana Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .